TreatSMA

Draft Managed Access Agreement for Spinraza has been published

Dear All,

As you will have seen, the final draft of the Managed Access Agreement (MAA) has been released, and there are a number of questions that it raises. The criteria are somewhat ambiguous and therefore we wanted to reassure you that we will be speaking with various people over the next couple of days to seek clarification and challenge some of the specifics.

Please rest assured we will keep you updated as soon as we have further information. In the meantime please bear with us and know that we are working hard to support the whole SMA community.

Best wishes,

The TreatSMA Team

Read the documents

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more